Lv5
939 积分 2023-11-13 加入
NK cell‐mediated anti‐tumor immune response to human prostate cancer cell, PC‐3: immunogene therapy using a highly secretable form of interleukin‐15 gene transfer
8天前
已完结
Functional atlas of vertebrate viral RNA elements that stabilize RNA and enhance translation
1个月前
已完结
Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study
1个月前
已完结
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
1个月前
已完结
Bispecific Antibodies
1个月前
已完结
Preclinical Proof-of-Concept of an mRNA-Based T Cell Engager Targeting BCMA, FcRH5, and GPRC5D for the Treatment of Multiple Myeloma
1个月前
已关闭
A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma
1个月前
已完结
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
1个月前
已完结
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
1个月前
已完结
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
1个月前
已完结
皖公网安备34019202002308
